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Abstract
Molecular functional and metabolic imaging allows
visualization of disease-causing processes in living
organisms. Here we present a new approach for the
functional molecular imaging (FMI) of endogenous
tyrosine kinase receptor activity using Met and its
ligand, hepatocyte growth factor/scatter factor (HGF/
SF), as a model. HGF/SF and Met play significant roles
in the biology and pathogenesis of a wide variety of
cancers and, therefore, may serve as potential targets
for cancer prognosis and therapy. We have previously
shown that Met activation by HGF/SF increases oxygen
consumption in vitro and results in substantial alter-
ation of blood oxygenation levels in vivo, as measured
by blood oxygenation level–dependent magnetic res-
onance imaging. Using contrast medium (CM) ultra-
sound imaging, we demonstrate here that HGF/SF
induces an increase in tumor blood volume. This
increase is evident in small vessels, including vessels
that were not detected before HGF/SF treatment. The
specificity of the effect was validated by its inhibition
using anti–HGF/SF antibodies. This change in tumor
hemodynamics, induced by HGF/SF and measured by
CM ultrasound, is further used as a tool for Met FMI in
tumors. This novel noninvasive molecular imaging
technique may be applied for the in vivo diagnosis,
prognosis, and therapy of Met-expressing tumors.
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Introduction
Tyrosine kinase growth factor receptors play an important
role in normal development, as well as in tumorigenicity
and metastasis. Alteration in their structure, quantity, ac-
tivity, or subcellular localization results in uncontrolled
cell growth and/or modification of cell differentiation,
which leads to tumor formation. Aberrant signaling through
the Met tyrosine kinase receptor and its ligand, hepa-
tocyte growth factor/scatter factor (HGF/SF), has been
described for a variety of human cancers (http://
www.vai.org/metandcancer). Overexpression of Met and/or
HGF/SF mutationally activates Met, and expression of both
Met and HGF/SF by the same cell (autocrine loop) contributes
to tumorigenesis [1]. Increased Met or HGF/SF expression in
human cancers is often associated with high tumor grade and
poor prognosis [2,3].
Met was found to be consistently and significantly overex-
pressed in colorectal carcinoma [4], malignant pleural meso-
thelioma [5], and gastric carcinoma [6]. In addition, increased
levels of Met or HGF/SF were reported in non–small cell lung
carcinomas, osteosarcomas, ovarian and pancreatic cancers,
and others (summarized in Maulik et al. [2]).
Met and HGF/SF were thoroughly studied in breast cancer.
The overexpression and coexpression of Met and HGF/SF
were reported in breast carcinoma tissues relative to benign
breast tissues [7]. In addition, HGF/SF expression was shown
to be a strong and independent predictor of recurrence and
survival in human breast cancer [8], and expression of Met
was found to be a strong independent predictor of decreased
survival [9,10]. Moreover, Met expression was demonstrated
as a diagnostic marker for identifying node-negative patients
who are likely to develop a more aggressive disease [10].
A disorganized and uncontrolled vascular supply, accompa-
nied by poor oxygenation and lowered pH, is a pathophysio-
logic hallmark of tumors. Growing tumors exhibiting vascular
deficiency or defective microcirculation are deprived of O2,
glucose, and other nutrients, resulting in a hypoxic micro-
environment that promotes the formation of new blood vessels
(for a review, see Folkman [11] and Hanahan and Folkman
[12]). Previous observations from our laboratory demonstrated
that activation of Met by HGF/SF increases cell oxygen con-
sumption and glycolysis [13]. Characterization of tumor meta-
bolic phenotype by magnetic resonance spectroscopy shows
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an increase in glucose consumption, glycolysis rate, and cy-
tosolic NADH/NAD ratio, compared with benign tissues [14].
In addition, hypoxia-inducible factor (HIF) proteins induce
the elevation ofMet levels under hypoxic conditions, resulting
in enhanced Met-HGF/SF signaling through Gab-1 and in-
creased cell motility [13,15].
We have previously shown that Met activation by HGF/SF
in vivo alters the hemodynamics of normal and malignant
Met-expressing tissues. Tumor-bearing BALB/c mice were
injected with HGF/SF and were imaged using magnetic
resonance imaging (MRI) and Doppler ultrasound. Organs
and tumors expressing high levels of Met showed the most
substantial alterations in blood oxygenation levels, as mea-
sured by blood oxygenation level–dependent MRI. No sig-
nificant alteration was observed in tumors or in organs that
do not express Met [16].
In this study, HGF/SF–induced hemodynamic alterations
were used to develop a novel functional molecular imaging
(FMI) method based on Met activation. This real-time imag-
ing takes advantage of ultrasound perfusion contrast me-
dium (CM) technology. We show here that Met activation
results in major hemodynamic changes, including increased
tumor blood volume, increased tumor area with significant
blood flow, and opening of existing blood vessels that
showed undetectable blood flow before the treatment. This
novel FMI technique can be used for the in vivo diagnosis,
prognosis, and therapy of Met-expressing tumors.
Materials and Methods
Animal Models
Two animal models were used in this study: 1) xenografts
of D1-DMBA-3 (DA3) (a cell line derived from a poorly
differentiated mammary adenocarcinoma using dimethyl-
benzanthracene) [17] in female BALB/c mice; and 2) xeno-
grafts of the human breast carcinoma cell line MCF7 in
athymic female nude mice. To induce tumors, 5  105 cells
were injected into the lower left mammary gland of mice. The
mice were allowed food and water ad libitum. Tumors were
allowed to grow until they had reached a volume of 0.5 to
1.5 cm2 (approximately 20 days) and then were imaged.
DA3 tumor-bearing mice were treated with HGF/SF–
neutralizing antibodies (Abs), as previously described [18].
In short, 0.2 mg of anti–HGF/SF (mAbs A-1, A-5, and A-7)
per 100 ml per animal was injected intraperitoneally before
CM ultrasound FMI.
All studies involving animal models were approved by
the Van Andel Research Institute Institutional Animal Care
and Use Committee or by the Committee of Animal Use and
Care at Tel Aviv University.
CM Ultrasound Imaging
Mice were anesthetized with 2% inhalation anesthesia
(isoflurane; Halocarbon Products, River Edge, NJ) delivered
with oxygen, using a nonrebreathing anesthetic delivery
system (Summit Anastasia Solutions, Bend, OR). Anesthe-
tized mice were placed on a heating pad to maintain body
temperature and to minimize temperature-induced changes
in blood flow. Hair surrounding the tumor area was removed
before imaging using a depilatory cream (Carter Product,
New York, NY). An imaging gel was placed on the tumor, and
a 27-gauge needle was inserted into the tail vein for repeated
intravenous injections. To retain the physiologic conditions
and to reduce the volume injected into the mice, first-pass
(bolus CM injection and imaging performed on the first time
that the CM was washed into the tumor), low-intensity, non-
destructive, CM-enhanced ultrasound imaging was per-
formed. The use of CM enables the detection of smaller
blood vessels relative to large blood vessels observed by
Doppler ultrasound. Ultrasound measurements were carried
out at 20 frames/sec, with a fixed 15L8s, 14-MHz linear
transducer power (18 dB/0.25 MI) (Sequoia 512; Acuson,
Mountain View, CA). To enable repeated imaging after
first-pass imaging, microbubbles were destroyed with a de-
structive imaging mode, allowing the detection of new micro-
bubbles in the flow to the imaged area.
To localize tumor boundaries and basal blood flow, color
Doppler ultrasound was performed. For high-temporal-
resolution FMI of Met, CM ultrasound imaging was per-
formed before and after HGF/SF treatment (Figure 1A).
Pre–HGF/SF contrast enhancement was measured by
intravenous injection of 150 ml of saline through the tail vein
and, 5 minutes later, by intravenous injection of 150 ml of CM
bolus I (15 mg/mouse, Definity Perflutren Lipid Microsphere;
Bristol-Myers Squibb Medical Imaging, Inc., N. Billerica, MA).
CM enhancement in the tumor was measured for 15 sec-
onds at a rate of 20 frames/sec (starting before the injection),
while CM enhancement reached plateau. Microbubble de-
struction mode was applied to clear the signal for additional
CM imaging (Figure 1A).
HGF/SF contrast enhancement was measured 20 min-
utes after HGF/SF injection (1024 U/mouse purified human
HGF/SF) by tail vein intravenous injection of 150 ml of saline
and, 5 minutes later, by intravenous injection of 150 ml of CM
bolus II (15 mg/mouse). CM enhancement in tumor was mea-
sured for 15 seconds at a rate of 20 frames/sec (starting
before the injection), while CM enhancement reached pla-
teau (Figure 1A).
Imaging settings were standardized and unchanged
throughout the experiment. Nomajor near-field artifacts were
encountered. Images were obtained by experienced sonog-
raphers who were not informed of the treatment status of the
animals throughout the study.
Image Analysis
Amouse cursor was used to outline the tumor’s regions of
interest (ROI) on the B-mode ultrasound image based on
structural criteria and echogenicity parameters [19]. To ana-
lyze the HGF/SF–induced alteration of intensity and volume,
a hypoechoic center was chosen to avoid the ill-defined
echogenic border that may contain normal tissues.
CM enhancement was calculated from time series images
(clips) using a dedicated functional molecular image analy-
sis software UIA (I-Labs, Petach Tikva, Israel) and a MICA
image analysis software (CytoView, Petach Tikva, Israel).
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Calculations were performed in several steps. 1) For pixel-
by-pixel analysis, signal percentage alteration was calcu-
lated by comparing the background intensity (the average
intensity of seven images before CM injection) with the
maximum signal intensity (SI; average intensity of seven
images after the CM reached plateau) for each pixel. 2) CM
alteration maps were calculated for each pixel and then
color-coded; blue tones represent reduction in signal and
red/yellow tones represent increased intensity. The defined
ROI outlined on the B-mode image were overlaid onto
appropriate maps. 3) The average pixel intensity of selected
ROI was calculated for each frame in the imaging sequence
and was fitted to an exponential curve. Gaussian smoothing
was applied to the average pixel.
Pre–HGF/SF CM enhancement was calculated from
the first bolus imaging as the difference between the maximal
SI (maximal enhancement) and the background (see step
immediately above). Post–HGF/SF CM enhancement was
calculated from the second bolus imaging as the difference
between the maximal SI (maximal enhancement) and the
background (see step immediately above).
Mapping of the effect of HGF/SF was performed by com-
paring the CM enhancement maps generated pre–HGF/SF
treatment (saline) and post–HGF/SF treatment for each
mouse. HGF/SF tumor enhancement effect maps demon-
strate alterations in contrast enhancement on HGF/SF treat-
ment (postmap  premap).
The effect of HGF/SF on tumor contrast enhancement
was calculated by analyzing the average maximal SI (per-
centage) on the pixels of the designated ROI before and after
HGF/SF treatment (Figure 1B). The effect of HGF/SF on
blood volume was calculated by using the average signal
calculated on the pixels of the ROI and by fitting it to an
exponential curve: Y = C  A(1  ebt), where C represents
background noise, A represents volume, t represents time,
and b represents flow. Statistical analysis was performed
using Student’s t test (with Microsoft Excel).
Results
HGF/SF Increases Hemodynamics in Met-Expressing
Tumors as Measured by Doppler and CM
Ultrasound Imaging
The effect of HGF/SF on tumor blood volume was as-
sessed using Doppler and CM real-time perfusion ultrasound
Figure 1. High-temporal-resolution FMI of Met: experimental layout and image analysis. (A) Experimental layout: to localize tumor boundaries and basal blood flow,
color Doppler ultrasound was performed. Baseline CM enhancement: mice were injected intravenously with 150 l of saline and, later, with 150 l of CM (15 g/
mouse; 5 minutes after the injection of saline), followed by a microbubble destruction mode that was necessary for additional CM imaging. HGF/SF CM
enhancement: CM imaging was performed by intravenous injection of 150 l of HGF/SF (1024 U/mouse purified human HGF/SF) [38] and, 20 minutes later, with
150 l of CM (15 g/mouse). (B) Image analysis: the effect of HGF/SF on tumor contrast enhancement was calculated by analyzing the average maximal SI
(percentage) on the pixels of the designated ROI before HGF/SF treatment (baseline) and after HGF/SF treatment.
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imaging. DA3 tumors expressing high Met levels were im-
aged before and after HGF/SF treatment. As previously
described [16], Doppler analysis showed an increase
in the number and in the size of blood vessels, indicating
an increase in blood flow to tumors following HGF/SF
injection (Figure 2, A and B). Ultrasound images are focused
on the tumor area. In color Doppler imaging, blood vessels
are depicted as blue and red spots; yellow and green rep-
resent regions of higher blood flow velocity. However, only
large blood vessels with high flow could be detected using
this technique.
To increase imaging resolution and to enable better quan-
tification, CM ultrasound imaging was performed. We mea-
sured the magnitude of the HGF/SF effect on tumor CM
enhancement before and after treatment. We found that, on
HGF/SF treatment, tumor enhancement was magnified,
showing higher rim and intratumoral enhancement (Figure 2,
C and D, yellow arrows). Both color Doppler and CM analy-
sis indicated an increase in blood volume to the tumors on
HGF/SF treatment.
To study the time dependency of the HGF/SF effect on
CM tumor enhancement, CM imaging was performed be-
fore, 20 minutes after, and 35 minutes after HGF/SF admin-
istration by repeated injection and destruction of CM. HGF/
SF– induced tumor CM enhancement was assessed for
each mouse by quantifying the SI in the tumor (ROI was de-
fined according to anatomy and structural criteria; Figure 3A)
for each time point (Figure 3B). Each fitting curve represents
the average pixel intensity of the selected ROI, as calculated
for each frame in the imaging sequence (20 frames/sec for
15 seconds after CM injection).
The increase in CM SI peaked by approximately two-fold
at 20 minutes after HGF/SF injection. For further analysis,
we chose 20 minutes as our optimal time for the increase in
HGF/SF–induced tumor contrast enhancement. CM en-
hancement levels were quantified and color-coded. Saline
(pre–HGF/SF treatment) (Figure 3C) and post–HGF/SF
treatment (Figure 3D) CM enhancements were mapped.
Brighter red and yellow colors represent higher SI. The
HGF/SF effect was mapped by subtracting the saline map
from the map obtained 20 minutes after HGF/SF treatment
(Figure 3E ); bright yellow represents a significant increase
in average SI on HGF/SF treatment. These results demon-
strate that HGF/SF treatment dramatically increases CM en-
hancement in the tumor area.
Specificity of HGF/SF Effects on Tumor CM
Enhancement—Validation by Inhibition Using
Anti–HGF/SF Ab
To validate the specificity of HGF/SF effects and to
ascertain that the hemodynamic responses are not influ-
enced by bolus injection of the CM, the effect of saline and
CM without HGF/SF was assessed. For each mouse, CM
enhancement was compared before and after saline injec-
tion (as described in the Materials and Methods section). To
evaluate the magnitude of the saline effect, we used statis-
tical analysis on a group of seven mice. Our results show that
saline and CM do not increase the average CM enhance-
ment (0.96-fold induction; P = .9).
To further validate the specificity of HGF/SF effects on
tumor CM enhancement, mice bearing DA3 tumors were
injected with an anti–human HGF/SF Ab cocktail, which
recognizes and neutralizes human HGF/SF and not the
endogenous mouse HGF/SF [18]. HGF/SF–induced tumor
CM enhancement was blocked when HGF/SF was admin-
istered concurrent with, or after, Ab administration. Quanti-
fied enhancement levels were color-coded and mapped
before and after HGF/SF treatment (Figure 4). Mapping of
enhancement differences showed that HGF/SF effects on
tumor CM enhancement were significantly inhibited when
Figure 2. HGF/SF induces increase in blood flow in a Met-expressing mammary adenocarcinoma tumor, as measured by Doppler and CM ultrasound imaging. A
mouse bearing a DA3 mammary adenocarcinoma tumor was injected intravenously with saline, followed by HGF/SF. Color Doppler ultrasound imaging was
performed (A) before HGF/SF treatment and (B) 20 minutes after HGF/SF treatment. Blood vessels are depicted as blue and red spots; yellow and green represent
regions of higher blood flow velocity. Doppler analysis showed an increase in the number and in the size of blood vessels on HGF/SF treatment (yellow arrows).
CM ultrasound imaging was performed (C) before HGF/SF treatment and (D) 20 minutes after HGF/SF treatment. On HGF/SF treatment, tumor enhancement was
magnified, as shown in higher rim and intratumoral enhancements (yellow arrows). Size bar, 1 cm.
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Figure 3. HGF/SF effect on tumor enhancement: time dependency and mapping. A mouse bearing a DA3 mammary adenocarcinoma tumor was injected
intravenously with saline, followed by HGF/SF. CM ultrasound imaging was performed before HGF/SF treatment and 20 minutes after HGF/SF treatment. (A) The
tumor was imaged using color Doppler ultrasound. For further calculation and quantification, the tumor was outlined (yellow mark) to specify the ROI based on
structural criteria. Size bar, 1 cm. (B) A graph representing alterations of CM enhancement on HGF/SF treatment for marked ROI (panel A, yellow). CM imaging
was performed before (blue curve), 20 minutes after (red curve), and 35 minutes after (green curve) HGF/SF treatment. Each curve demonstrates the average
tumor enhancement after CM injection, calculated for 15 seconds (for each frame; 20 frames/sec). To normalize the signal, the background intensity was calculated
as 100%. Percent SI increased by approximately two-fold and peaked 20 minutes after HGF/SF injection. (C–E) Mapping HGF/SF effects on tumor enhancement.
CM ultrasound SI color-coded maps were generated (C) before HGF/SF injection and (D) 20 minutes after HGF/SF injection. Brighter red and yellow colors
represent higher SI (D versus C). The HGF/SF effect was mapped as the difference in SI before and after HGF/SF injection (E), where bright yellow represents a
significant increase in average SI on HGF/SF treatment.
Figure 4. Inhibition of HGF/SF effects on tumor enhancement by HGF/SF–neutralizing Ab. A mouse bearing a DA3 mammary adenocarcinoma tumor was
injected intravenously with saline, followed by HGF/SF. The tumors were injected with anti –human HGF/SF Ab cocktail before treatment or with HGF treatment.
CM ultrasound imaging was performed before HGF/SF treatment and 20 minutes after HGF/SF treatment. (A) The tumor was imaged using color Doppler
ultrasound. For further calculation and quantification, the tumor was outlined (yellow mark) to specify the ROI based on structural criteria. Size bar, 1 cm. (B–D) CM
ultrasound SI color-coded maps were generated (C) before HGF/SF + HGF/SF–neutralizing Ab treatment and (D) 20 minutes after HGF/SF + HGF/SF–
neutralizing Ab treatment. Brighter red and yellow colors represent higher SI. (B) The blocking of the HGF/SF effect was mapped as the difference in SI before and
after HGF/SF injection, where brighter color represents an increase in average SI on HGF/SF treatment.
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the animals were treated with the Ab cocktail. Overall, an
average inhibition of 82% was detected in all mice tested
(n = 7, P = .05).
HGF/SF–Induced Alteration of Tumor Blood Volume
and Velocity
The alteration in CM enhancement on HGF/SF treatment
was assessed for each mouse by comparing the CM en-
hancement before and after HGF/SF treatment (as de-
scribed in the Materials and Methods section). To evaluate
the magnitude of the HGF/SF effect, we used statistical
analysis on a group of 18 mice (Figure 5A). Our results show
that HGF/SF increased the average CM enhancement by
1.8-fold (P = .004).
To further validate the HGF/SF effect on tumor blood
volume, we assessed the tumor areas with significant CM
enhancement in response to HGF/SF treatment. Blood
vessels/pixels that show measurable enhancement before
HGF/SF treatment were designated as ‘‘preopened’’ vessel
areas, whereas ‘‘newly opened’’ blood vessel areas refer to
areas in which vessels that did not show any measurable
enhancement before treatment had measurable enhance-
ment on treatment. We calculated the differences in the
number of pixels with measurable CM enhancement in the
tumor area before and after treatment (Figure 5B). HGF/SF
increases the areas with significant enhancement by 2.219-
fold, on average (n = 18, P = .0012).
HGF/SF–induced changes in blood velocity and volume
were studied by calculating the average tumor CM enhance-
ment from time series images (20 frames/sec for 15 seconds
after CM injection) and by fitting them to an exponential curve
(see the Materials and Methods section). A 1.5-fold volume
increase was observed on HGF/SF treatment in preopened
vessels (n = 18, P < .0001), whereas in newly opened ves-
sels, a 4.49-fold increase (n = 18, P < .0001) was obtained in
regions that did show very low enhancements before HGF/
SF treatment (Figure 5C). HGF/SF showed a small, insignifi-
cant effect on blood velocity in all blood vessels. These
analyses demonstrate that HGF/SF opens new blood ves-
sels with high volume and low velocity.
HGF/SF–Induced Increase in Tumor Blood Volume
in the Human Breast Cancer Cell Line MCF7
To study the HGF/SF treatment effect on tumor blood
volume in a human breast cell line, we used nude mice bear-
ing MCF7 tumors. The alteration of CM SI was studied for
each mouse by comparing the CM enhancement before
and after HGF/SF treatment. Statistical evaluation of the
magnitude of the HGF/SF effect showed that HGF/
SF increases the average CM enhancement by 1.37-fold
Figure 5. Quantification of HGF/SF– induced increase in tumor volume. Eighteen mice bearing DA3 mammary adenocarcinoma tumors were injected
intravenously with saline, followed by HGF/SF. CM ultrasound imaging was performed before HGF/SF treatment and 20 minutes after HGF/SF treatment. (A) HGF/
SF increases CM SI. The average calculated alteration of SI (pixel intensity) before HGF/SF treatment (saline) and after HGF/SF treatment (HGF/SF) is shown.
Standard error bars are indicated. HGF/SF increased the average CM signal enhancement by 1.8-fold ( P = .004). (B) HGF/SF increases the area with measurable
flow. Areas that showed a detectable signal before HGF/SF treatment were designated ‘‘preopened’’; areas that did not show a detectable signal before HGF/SF
treatment and showed a detectable signal after HGF/SF treatment were designated ‘‘newly opened.’’ A comparison of areas in the ROI with detectable blood
flow before and after HGF/SF treatment showed a 3.62-fold increase (n = 18, P < .0001) in areas with significant enhancement. (C) HGF/SF increases blood
volume. Areas that showed a detectable signal before HGF/SF treatment were designated ‘‘preopened’’; areas that did not show a detectable signal before HGF/
SF treatment and showed a detectable signal after HGF/SF treatment were designated ‘‘newly opened.’’ The average tumor CM enhancement before HGF/SF
treatment (gray bars) and after HGF/SF treatment (black bar) that was calculated from time series images (20 frames/sec for 15 seconds after CM injection) of
the preopened and newly opened regions was fitted to an exponential curve Y = C  A(1  et), where C represents background noise, A represents volume,
 represents velocity, and t represents time. A 1.5-fold volume increase was observed on HGF/SF treatment in preopened vessels (n = 18, P < .0001), whereas in
newly opened vessels, a 4.49-fold increase (n = 18, P < .0001) was obtained. These analyses demonstrate that HGF/SF opens new blood vessels with high volume.
Met Molecular Imaging: HGF/SF Increases Blood Volume Tsarfaty et al. 349
Neoplasia . Vol. 8, No. 5, 2006
(Figure 6; n = 7, P = .01). HGF/SF–induced changes in blood
velocity and volume were studied by calculating the aver-
age tumor CM enhancement from time series images
(20 frames/sec for 15 seconds after CM injection) and by
fitting them to an exponential curve (see the Materials and
Methods section). A 1.2-fold volume increase was observed
on HGF/SF treatment (n = 7, P < .025).
Met levels in MCF7 cells are lower that those in DA3 cells
[20,21]; therefore, our results may reflect differences in Met
levels between these two cell lines and may indicate that the
HGF/SF–induced increase in blood volume is dependent on
Met levels in the tumor.
Discussion
We have previously reported that tumors expressing high
levels of Met show the most substantial alterations in blood
oxygenation levels, as measured by blood oxygenation
level–dependent MRI. No significant alteration was ob-
served in tumors or in organs that do not express Met [16].
Diagnostic ultrasound has the advantage of producing
real-time images with excellent temporal resolution. How-
ever, the task of mapping tumor vessels with ultrasound has
previously been difficult due to acoustic blood signals, which
are below that of the surrounding vessel walls. These low-
signal levels prevent traditional Doppler techniques from
being used to accurately assess tumor microvascular flow
rates [22]. Moreover, blood flow rate in the tumor may be sig-
nificantly lower than that in normal tissues due to the highly
tortuous vessel structure and increased flow resistance [23].
The use of intravascular microbubble contrast agents in-
creases ultrasound sensitivity to capillary-sized vessels and
very low flow rates while maintaining the ability to detect
morphologic information from traditional B-mode ultrasound
imaging [24]. Some studies provided preliminary evidence
that microbubble-induced enhancement could be useful in
tumor diagnosis [25].
We have further developed a first-pass CM ultrasound
technique that takes advantage of several recent improve-
ments in ultrasound imaging technology [26]. We are em-
ploying a nondestructive method to measure the first pass.
This flow measurement technique is based on the assump-
tion that contrast microbubbles enter tumor circulation at a
constant rate [27]. We have documented that an intensity
change in specific CM ultrasound signals is detectable after
HGF/SF injections. We show here that Met activation re-
sults in an increased tumor area with significant blood vol-
ume and in major increases in total tumor blood volume. The
increase in blood volume is a consequence of the opening of
blood vessels that, before treatment, showed undetectable
blood volume and are considered ‘‘newly opened,’’ with a
4.49-fold increase after HGF/SF treatment. It was recently
shown that tumors with small, flattened vessels show a
significantly higher resistance to microbubble perfusion than
to MRI contrast agents and appear scarcely vascularized on
CM examination, despite a vessel volume that is adequate
for normal function [28]. Here we demonstrate that HGF/SF
reduces the resistance of tumor vessels.
Aggressive tumors often have insufficient blood supply,
partly because the tumor cells grow faster than endothelial
cells and partly because a newly formed vascular supply is
disorganized [29,30]. Under such microenvironment, tumor
cells are exposed to both hypoxia and nutrient deprivation
[31,32]. In tumor cells exposed to hypoxia, HIF-1, which is a
transcription factor composed of HIF-1a and HIF-1b subunits
[33], is activated to promote the transcription of several
genes, such as glucose transporters, glycolytic enzymes,
and angiogenic factors [34]. The importance of angiogenesis
in tumor growth and metastasis has been well documented
[11,12]. Tumor enlargement and metastasis formation are
dependent on this process. Angiogenesis creates new blood
vessels to the tumor, reduces anaerobic conditions in the
tumor, and enables tumor growth and metastasis progres-
sion [12]. In this paper, we suggest an additional mechanism
for tumor cell survival under anaerobic conditions. A tyrosine
kinase oncogenic signal induces an increase in blood flow
and in blood volume to the tumor and reduces anaerobic
conditions. We mapped the alteration in CM SI induced by
HGF/SF. This mapping is an estimation of blood volume al-
terations in different regions of the tumor.
The data presented here demonstrate, for the first time, a
dramatic increase in blood flow to the tumor as a result of the
activation of the Met tyrosine kinase growth factor receptor,
which plays a major role in tumor proliferation and metas-
tasis. The dramatic increase in the area of significant flow
and tumor blood volume is shown to be primarily a conse-
quence of the opening of blood vessels that did not show de-
tectable flow before HGF/SF treatment. Based on regular
color Doppler or CM ultrasound imaging, these areas can be
misinterpreted as necrotic areas.Met FMI usingHGF/SF treat-
ment reveals that these areas contain viable tumor tissues.
A competition theory–based model proposed by Gatenby
[35] suggests that the metabolic changes associated with
transformation manipulate the tumor microenvironment in
a way that favors the growth of tumor cells at the expense
Figure 6. HGF/SF induces increased SI: human breast cancer cells. Seven
nude mice bearing MCF7 breast adenocarcinoma tumors were injected
intravenously with saline, followed by HGF/SF. CM ultrasound imaging was
performed before HGF/SF treatment and 20 minutes after HGF/SF treatment.
The average calculated alteration of SI (percentage change in pixel intensity)
before HGF/SF treatment (saline) and after HGF/SF treatment (HGF/SF) is
shown. Standard error bars are indicated. HGF/SF increased the average CM
signal enhancement by 1.37-fold (P = .01).
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of normal cells. We demonstrate that elevation of tyrosine
signaling in the tumor will also increase blood flow to the
tumor. Increased flow in blood vessels leads to increased
levels of oxygen, glucose, and other nutrients supplied to
the tumor.
The molecular mechanisms of the Met-HGF/SF–induced
alteration of hemodynamics are not fully understood. We
have previously suggested two basic mechanisms (direct
and indirect) of the effect of Met signaling on tumor cells [16].
The indirect mechanism suggests that HGF/SF affects the
blood vessels and changes the systemic blood flow. Met
signaling was shown to be activated in endothelial cells,
favoring the model of blood vessel activation by HGF/SF.
The direct mechanism suggests that HGF/SF, through Met
signaling in tumor cells, causes local hypoxia, which in turn
induces an alteration in blood flow. In addition, we have pre-
viously shown that Met induces mitochondrial activity [36],
and we were able to show recently that Met activation
induces mitochondrial hyperpolarization and ATP synthesis
(data not shown). The direct mechanism is supported by
published data showing that Met is involved in the HIF-1a
hypoxic pathway [37].
Several new molecular therapies, including the potential
use of anti-Met therapy, are cytostatic rather than cytotoxic—
meaning that these therapies inhibit cell growth rather than
promote cell death. Classic imaging measuring tumor loca-
tion, diameter, and volume may no longer provide an accu-
rate reading of a tumor in its cytostatic state and of the
patient’s overall condition. Moreover, the traditional stan-
dards for drug dosing are rendered obsolete because mo-
lecularly targeted therapies may be largely free of side
effects. Met FMI, as demonstrated in this paper, can serve
as a powerful system that measures the potential effect of
anti-Met inhibitors, can be used to screen patients who might
benefit from an anti-Met treatment, and can be used to follow
up on treatment response.
The results presented here further demonstrate the
complex biology induced by the tumor as it recruits more
energy resources from its host tissue. Recruitment of en-
ergy by the tumor does not end with angiogenesis; it pro-
ceeds with increased blood flow to the tumor, which supplies
extensive energy requirements that allow tumor growth
and metastasis.
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